- Home
- FLNC vs PRAX Comparison
FLNC vs PRAX Comparison
Compare FLNC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- PRAX
- Stock Information
- Founded
- FLNC 2018
- PRAX 2015
- Country
- FLNC United States
- PRAX United States
- Employees
- FLNC N/A
- PRAX N/A
- Industry
- FLNC Industrial Machinery/Components
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- PRAX Health Care
- Exchange
- FLNC Nasdaq
- PRAX Nasdaq
- Market Cap
- FLNC 802.6M
- PRAX 950.8M
- IPO Year
- FLNC 2021
- PRAX 2020
- Fundamental
- Price
- FLNC $7.54
- PRAX $48.78
- Analyst Decision
- FLNC Hold
- PRAX
- Analyst Count
- FLNC 20
- PRAX 0
- Target Price
- FLNC $8.03
- PRAX N/A
- AVG Volume (30 Days)
- FLNC 4.2M
- PRAX 541.9K
- Earning Date
- FLNC 08-11-2025
- PRAX 08-04-2025
- Dividend Yield
- FLNC N/A
- PRAX N/A
- EPS Growth
- FLNC N/A
- PRAX N/A
- EPS
- FLNC N/A
- PRAX N/A
- Revenue
- FLNC $2,449,087,000.00
- PRAX $7,765,000.00
- Revenue This Year
- FLNC $2.98
- PRAX N/A
- Revenue Next Year
- FLNC $25.19
- PRAX $3,567.38
- P/E Ratio
- FLNC N/A
- PRAX N/A
- Revenue Growth
- FLNC 14.26
- PRAX 338.45
- 52 Week Low
- FLNC $3.46
- PRAX $26.70
- 52 Week High
- FLNC $24.00
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- FLNC 45.91
- PRAX 50.21
- Support Level
- FLNC $7.11
- PRAX $44.15
- Resistance Level
- FLNC $8.69
- PRAX $48.68
- Average True Range (ATR)
- FLNC 0.61
- PRAX 2.78
- MACD
- FLNC -0.18
- PRAX -0.34
- Stochastic Oscillator
- FLNC 29.17
- PRAX 49.73
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.